PLX
Protalix Biotherapeutics Inc
2.70$
-1.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | +16.5% | -186.2% | – | -2.8% | -226.7% | – | – | – | +985.0% | -147.2% | – | |
| – | +22.0% | -13.4% | -0.9% | +3.1% | +1.5% | +3.6% | +4.0% | +3.3% | +4.0% | +4.4% | +0.5% | – | |
| – | +24.6% | -28.2% | +1.7% | -37.9% | +5.5% | -17.4% | -20.9% | +40.0% | +22.4% | -27.3% | -25.2% | – | |
| – | – | +28.3% | -126.6% | – | – | – | – | – | – | -56.1% | -713.0% | – | |
| – | -44.1% | +139.2% | -71.2% | -49.4% | +388.5% | -28.0% | +40.8% | +15.5% | -19.1% | +88.8% | -22.1% | – | |
| – | -98.4% | +77.2% | -70.3% | – | -175.4% | -98.0% | +40.4% | +15.1% | +120.6% | – | -186.1% | – | |
| – | – | – | – | – | – | +40.0% | +80.9% | +0.0% | +1.6% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -100.0% | – | – | – | – | +40.0% | -19.1% | +123.7% | -98.4% | +2.7% | -100.0% | – | |
| – | – | +10.8% | -206.6% | – | -290.7% | – | – | – | – | +2,448.0% | -151.6% | – | |
| – | – | +7.3% | -205.3% | – | -11.2% | -250.4% | – | – | – | +1,206.9% | -151.7% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.